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Abstract The pliability of cancer cells to mutate into several different phenotypes in an attempt to find one that will
survive and colonize at the metastatic site is a tremendous ‘‘hurdle’’ to overcome in designing novel cancer therapeutics.
New targets of therapy are essential if we are to effectively overcome the evasiveness of cancer. The interaction between
the tumor cell and the surrounding microenvironment creates a vicious cycle that perpetuates disease survival and
progression. The future of cancer therapy resides in the ability to focus on the recruited and exploited relationships of
the cancer cell with the host environment. These therapies target cancer cell growth early and interrupt the vicious cycle
that is created by the tumor cells interacting with bone components by inhibiting osteoclasts, osteoblasts, stromal cells,
and endothelial cells. They alter the bone microenvironment, creating a hostile ‘‘soil’’ that prevents the ‘‘seed’’ from
developing into bone metastases and represent a potential new platform for the development of prostate cancer
therapeutics. J. Cell. Biochem. 96: 439–446, 2005.  2005 Wiley-Liss, Inc.
Key words: prostate cancer; bone metastasis; cancer therapy
In recent years, the incidence of prostate
cancer has risen consistently and the disease is
responsible for more gender-specific cancer-
related deaths in men than any other cancer.
The American Cancer Society estimates that
during 2005 about 232,090 new cases of pro-
state cancer will be diagnosed in the US and
30,350menwill die ofmetastatic disease. About
1 man in 5 will be diagnosed with prostate
cancer during his lifetime, and 1 man in 33 will
die of this disease. As the population ages, these
numbers are expected to increase. Prostate
cancer is curable if detected when confined to
the prostate gland but attempts at treatment
and cure havemet with limited success once the
disease has spread outside the prostate.
Approximately 80% of patientswho have died
of advanced hormone refractory prostate cancer
have clinical evidence of bone metastases and
100% have histologic bone involvement [Saitoh
et al., 1984; Bubendorf et al., 2000; Roudier
et al., 2003]. The development of bone disease is
believed to follow the seed and soil hypothesis
first described byStephenPaget in 1889 [Fidler,
2003]. In advanced prostate cancer patients,
tumor cells (seed) in the bloodstream invade the
marrow space (soil) forming osseous lesions.
Metastatic prostate cancer bone lesions are the
result of a complex interplay between the cancer
cells themselves and the bone microenviron-
ment, resulting in a heterogeneous disease that
induces a combination of both osteolytic and
osteoblastic lesions. The pathogenesis of osteo-
lytic and osteoblastic bone metastases involves
interactions between osteoclasts, osteoblasts,
endothelial cells, fibroblasts, adipocytes, bone
marrow precursor cells, cells of the immune
system, the extracellular matrix (ECM), and
the cancer cells (Fig. 1). A paradigm shift from
an initial treatment strategy that primarily
targets the tumor cell directly, i.e., traditional
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chemotherapy, to new therapies that exploit the
interactions and contributions of the various
cells and elements of surrounding microenvir-
onment to the development of the metastatic
lesions is now being explored and already
exploited to improve outcomes for patients with
advanced prostate cancer.
DEVELOPMENT OF A NEW PARADIGM FOR
THE TREATMENT OF PROSTATE CANCER
COMBINING TARGETED THERAPIES
Targeting the Tumor Cell Burden Early in the
Metastatic Process
The canonical treatment paradigm for virtu-
ally all cancers, including prostate cancer, has
been to target the tumor cell directly. Che-
motherapy is generally used in patients with
advanced, clinically evident disease. Recently,
for the first time, trials have demonstrated that
treatment with docetaxel increases survival
in patients with hormone refractory prostate
cancer [Tannock et al., 2004]. Current che-
motherapy regimens may debulk the tumor
and palliate symptoms, but cannot completely
eradicate late stage disease. The advent of
prostate specific antigen (PSA) as a molecular
marker has made early detection of disease
and disease recurrence possible. Disease recur-
rence after radical prostatectomy can now be
reliably detected in patients with a PSA of 0.1
ng/ml or potentially lower with supersensitive
assays [Yu et al., 1997]. In addition, circulating
tumor cells can be detected in many of these
patients with rising PSA, suggesting that
the cancer is capable of spreading early in
the disease course [Loberg et al., 2004]. It is
generally considered that a serumPSAof 4.0ng/
ml is roughly equivalent to a tumor of one
cubic centimeter which is equivalent to one
billion tumor cells [Fukatsu et al., 2003]. It is
possible, therefore, to potentially detect tumor
recurrence when there are approximately 1–
25 million cells present.
The argument for treating micrometastatic
disease early in the cancer course is not novel
and is based on at least four premises [Norton
and Simon, 1977; DeVita, 1983]. First, in a
perfect system, in vitro or in vivo, one dose of
chemotherapy kills one log of tumor cells
[DeVita, 1983]. By simple tumor burden, it is
easier to eradicate a smaller tumor with the
same number of chemotherapy cycles compared
to a large tumor. Second, microscopic foci of
cancer cells grow at an exponential rate and are
easier to eradicate with traditional cytotoxic
agents [Norton and Simon, 1977]. Third, as a
tumor grows, heterogeneity of tumor cells
continues to evolve with resulting chemo-resis-
tance. Fourth, prostate cancer cells secrete
several factors that stimulate the surrounding
bonemicroenvironmentwhich in turn promotes
growth of the cancer cells, creating a vicious
cycle of tumor cell–microenvironment interac-
tions that drive the progression of metastatic
disease [Chung, 2003]. The cancer cells secrete
factors which stimulate osteoclasts to break
down bone, as well as proteases such as PSA
and urokinase which break down the ECM.
This catabolism of the bone microenvironment
results in the release of multiple factors that
activate osteoblasts and stimulate the growth of
the cancer cells (see Fig. 2).
Targeting Osteoclasts and Osteolysis
Although osseous metastastic lesions from
prostate cancer are predominantly osteoblastic,
the presence of osteoclastic activity within
metastatic lesions is also vitally important to
the understanding and treatment of pro-
state cancer. Osteoclasts are a unique cell type
derived from hematopoetic stem cells and
express a large number of highly specific
enzymes designed to breakdown bone. These
Fig. 1. The hexagon of prostate tumor cell–bone microenvir-
onment interactions. The relationship between the tumor cell
and the surrounding tissue is a complex environment. Tumor
cells interact with the extracellular matrix (ECM), stromal cells,
immune system, osteoblasts, osteoclasts, and endothelial cells to
coordinate a sophisticated series of interactions to promote
tumor cell survival and proliferation leading to a ‘‘hexagon of
pain’’ for patients with advanced prostate cancer. These
interrelationships identify a paradigm shift in understanding
prostate cancer growth in bone and lead to the ability to design
targeted therapies to interrupt the vicious cycle of the tumor cell
with its microenvironment.
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cells are known to be activated by a variety of
growth factors, many of which are secreted by
prostate cancer cells (i.e., TGFb, EGF, IL-1, IL-6
etc.). The activation of osteoclasts leads to the
catalysis of the bone matrix and subsequent
release ofmultiple growth factors and cytokines
which are capable of stimulating metastatic
growth in the bone [Keller, 2002]. The release
of these factors aid in further chemotaxis of
prostate cancer cells and also creates an en-
vironment suitable for prostate cancer growth
and proliferation.
Several strategies have been developed to
inhibit osteoclast activity. Newer, nitrogen-
containing IV bisphosphonates, which target
osteoclasts and osteolytic lesions, have recently
proven efficacious in the palliative care of
prostate cancer patients. Bisphosphonates are
analogs of pyrophosphate, a normal constituent
of the bonematrix, which binds to bone surfaces
(hydroxyapatite crystals) making them less
available to osteoclast resorption. Additionally,
bisphosphonates inhibit recruitment of osteo-
clast precursors, prevent the migration of
osteoclasts towards bone, and inhibit the pro-
duction of prostaglandin-E2, Interleukin-1,
and other proteolytic enzymes. Treatment of
hormone refractory prostate cancer patients
with chemotherapy plus the bisphosphonate
zolendronic acid (Zometa1) demonstrated a
decrease in skeletal related events such as
fractures and the need for palliative radiation
therapy. Zolendronic acid is nowapproved as an
adjunctive treatment for patients with andro-
gen independent prostate cancer [Winquist and
Berry, 2004].
Other strategies to inhibit osteoclast activity
are under development, including inhibition of
the parathyroid related peptide (PTHRP) and
RANK-L/RANK signaling axes which induce
osteoclast activity [14]. Selective estrogen
receptor modulators (SERMs) may be able to
decrease the bone resorption associated with





























Fig. 2. Diagrammatic representation of bone-specific prostate
cancer metastasis. A variety of factors are released from both the
tumor cell and the bone microenvironment that participate in
successful metastasis and growth of neoplasms. [TC, tumor
cell; OB, oseteoblast; OC, osteoclast; S, stromal cell; PTHrp,
parathyroid hormone related protein; SDF, stromal derived
factor; IL-1, interleukin 1; IL-1ra, interleukin 1 receptor
antagonist; IGFBP-2, insulin-like growth factor binding protein
2; IL-6, interleukin 6; IL-8, interleukin 8; PGE2, prostaglandin
E-2; TGF, transforming growth factor; EGF, epidermal growth
factor; BMP, bone morphogenic protein; ET-1, endothelin-1;
CXCL7, chemokine (C-X-C motif) ligand 7; CCL18, chemokine
(C-Cmotif) ligand 8; ICAM-1, intracellular adhesionmolecule-1].
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affect parathyroid hormone activity (PTH) and
Vitamin D metabolism resulting in altered
calcium homeostasis [Jiann et al., 2002].
The local effects of SERM therapy include the
inhibition of osteoclast activity, the inhibition
of osteoblast activity, and direct cytotoxic
effects to tumor cells [Taranta et al., 2002].
Thus, SERMs (e.g., tamoxifen, clomiphene, and
raloxifene) are non-steroidal compounds that
act as estrogen receptor agonists and antago-
nists depending on the target tissue.
Treatment with osteoclast inhibitors early in
disease recurrence may delay the development
of osseous metastases by altering normal bone
homeostasis. In animal models it has been
demonstrated that prostate cancer cells ‘‘seed’’
or ‘‘home’’ to areas of high bone metabolism
[Kalikin et al., 2003]. It can be postulated,
therefore, that decreasing bone metabolism via
long-term osteoblastic inhibition throughout
the disease course may decrease successful
seeding of tumor cells in potential metastatic
sites. At least one clinical trial demonstrated an
increase in survival with long-term bispho-
sphonates treatment in women with metastatic
breast cancer [Diel et al., 2004]. Clinical trials




Themost commonhistology of prostate cancer
bone metastases is a disorganized osteoblastic
response and the osteoblast plays a key role
in the bone metastasis microenvironment.
Several growth factors (e.g., insulin-like growth
factor 1, transforming growth factor beta,
endothelin-1, fractalkine) produced by osteo-
blasts and osseous stromal cells act as chemo-
attractants for prostate cancer cells, and also
promote tumor growth and proliferation
[Shulby et al., 2004].
To date, targeting the osteoblasts has been
an underdeveloped area of research, however,
the compounds that inhibit the endothelin
axis have proven to be an excellent example
of osteoblast targeted therapy. Endothelin-1
(ET-1) was originally identified as a vasoactive
peptide released from the vascular endothelium
to regulate blood pressure and vascular tone by
promoting vasoconstriction [Withrington et al.,
1989]. Recently, ET-1 has been shown to be an
important mediator of tumor growth and tumor
cell survival in prostate cancer [Mohammad
andGuise, 2003]. Initial evidence in both breast
cancer and prostate cancer preclinical models
demonstrated that the use of specific receptor
antagonists to ET-1 could reduce the rate of
bone formation and the frequency of bone
metastases both in vitro and in vivo [Mundy,
2002; Guise and Mohammad, 2004]. Several
compounds are under investigation as a novel
class of chemotherapeutic agents that target
the ETA (ET-1 receptor), including Atrasentan,
an orally bioavailable ETA receptor inhibitor,
disrupts the bonemicroenvironment by inhibit-
ing the osteoblastic axis and has been studied in
several phase II clinical trials in prostate cancer
[Lee, 2003; Nelson et al., 2003; Zonnenberg
et al., 2003; Nelson, 2005].
Targeting the Stromal Cells
The stromal elements that participate in
and support cancer growth include fibroblasts,
smooth muscle cells, endothelial cells, and in-
flammatory cells [11]. It appears that targeting
these stromal components of the microenviron-
ment may be effective in reducing the develop-
ment of metastases. Bagshaw and colleagues
noted that there was a reduction in the fre-
quency ofmetastatic lesions to the lumbar spine
in prostate cancer patients treated prophylacti-
cally with high dose radiation (35–60 Gy) to the
lumbar spine [Bagshaw et al., 1990]. A similar
finding was reported in breast cancer patients
treated with sternal radiation [Grimard et al.,
1988].While radiation can potentially eradicate
micrometastatic disease, it has also been postu-
lated that these doses of radiation aremore than
adequate to destroy the replicative potential of
the bone endothelial cells. This would result in
the inability to vascularize a growing tumor in
these radiated sites [Abdollahi et al., 2003].
Irradiationmay also reduce bonemetastases by
inducing other bone stromal cell damage,
osteocyte damage, and/or osteoblast damage,
creating an unfavorable microenvironment for
the tumor cells to colonize.
Another approach to altering the microenvir-
onment utilizes systemic radioisotopes instead
of local irradiation. Radioisotopes exert their
palliative effect by combining with the calcium
component of hydroxyapatite in damaged bone
[Neves et al., 2002]. Radioisotopes are effective
therapeutic agents for the management and
palliation of bone-specific disease due to the
high levels of retention by bone metastases
(highest in damaged bone, less in normal bone
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tissue, and no retention outside of bone). The
most common radioisotopes are strontium-89
and samarium-135 lexidronam ethylene dia-
mine tetramethylene phosphonate [Graham
et al., 1999; Dafermou et al., 2001; Palmedo
et al., 2003]. These radionuclides are beta-
emitting radioisotopes that differ primarily in
their radioactive half-lives and the tissue pene-
trance of their beta particles. Adding systemic
radioisotopes to chemotherapy regimens for
patientswith advanced prostate cancer appears
to increase response rates and survival [Tu
et al., 2001; Akerley et al., 2002]. Further
exploration of how this could be applied to the
human disease setting is being investigated in
preclinical and clinical settings.
Targeting Cytokine and Growth Factor
Stimulation of Endothelial Cells
Another important pathway for targeting the
tumorigenic potential of the microenvironment
is through the interruption of cytokine and
growth factor production. Multiple cytokines
are important in cancer development, both those
that stimulate cancer cell growth directly and
those that target the growth of supporting
cells such as endothelial cells. Vascular endo-
thelial growth factor (VEGF) has emerged as
the primary cytokine secreted by tumor cells
which stimulates new blood vessel growth. The
VEGF family of growth factors consists of five
related proteins which have been implicated
in angiogenesis (VEGF-A, VEGF-B, VEGF-C,
VEGF-D, VEGF-E). There are three VEGF
receptors (VEGFR1, VEGFR2, and VEGFR3)
that appear to play an important role in the
angiogenesis of prostate cancer [Drevs et al.,
2005]. One strategy to utilize this pathway in
prostate cancer treatment is to block the inter-
action of VEGF with its receptors. This can be
done by using antibodies to VEGF (i.e., bevaci-
zumab), antibodies to the VEGF receptors
themselves, or by inhibiting the tyrosine kinase
activity of the receptor.One example of this type
of agent being tested in androgen independent
prostate cancer phase II trials is PTK787, an
orally administered amino-phthalazine that
blocks all known VEGF receptors [Drevs et al.,
2005].
A second strategy targeting the microenvir-
onment involves inhibiting the growth of new
blood vessels by blocking integrin function.
Tumor-related blood vessels sprout into
the ECM in a process that is mediated by
the integrins avb3 and avb5 which bind to a
variety of ECMmolecules including vitronectin
[Maragoudakis et al., 2002]. Integrins avb3 and
avb5 bind factors such as vitronectin containing
the amino acid sequence Arg-Gly-Asp (RGD),
which appears to be critical in mediating the
ligation signal, allowing endothelial cells to
attach to the ECM [Meerovitch et al., 2003].
This interaction can be blocked by EMD 121974
(Cilengitide), the inner salt of a cyclized penta-
peptide, or an antibody to avb3 (Vitaxin) [Posey
et al., 2001]. Currently, both compounds are in
clinical trials for androgen independent pros-
tate cancer. It is generally believed that target-
ing tumor-associated blood vessel growth is a
more successful therapeutic strategy when a
tumor is small, and should be applied early in
the disease course.
Targeting the Destruction of the
Extracellular Matrix
The ECM of the bone includes not only the
calcium hydroxyapatite of the bone itself but
also the traditional ECM of the stromal and
cancer cells. As a tumor grows, it releasesmulti-
ple proteases including PSA, urokinase, and
matrix metalloproteinases which break down
the ECM to allow for growth, invasion of new
blood vessels, and metastasis. Several therapy
modalities have been tried and are currently
under investigation that targets these enzymes.
Tetracyclines are a family of compounds (e.g.,
doxycycline and tetracycline) that have been
used as antibiotics but have recently been
shown to inhibit matrix metalloproteinases
(MMPs). MMPs are known to be essential to
the invasion and metastatic potential of many
cancers [Saikali and Singh, 2003]. Currently
Col-3, a modified tetracycline molecule, is in
phase I clinical trials in a variety of solid tumors
including hormone refractorymetastatic cancer
[Rudek et al., 2001]. The effects of tetracycline
and doxycycline on MMP activity has led to
the development of ongoing clinical trials in
breast cancer and prostate cancer [Saikali and
Singh, 2003]. Green tea may also inhibit MMPs
activity. Green tea has been shown to have
important chemopreventive properties attribu-
ted to its high polyphenolic content, specifica-
lly epigallocatechin-3-gallate (EGCG) [Adhami
et al., 2003]. Administration of green tea to the
transgenic adenocarcinoma of the mouse pros-
tate (TRAMP)model resulted in an inhibition of
VEGF and MMP activity [Adhami et al., 2003].
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Targeting the Immune System With Vaccines
Cancer cells evade the immune system
through multiple strategies and a considerable
amount of research has focused on targeting the
immune system either by enhancing the immu-
nogenicity of the tumor cells directly or inducing
a more effective immune response. APC8015
(Provenge1) is an investigational therapeutic
vaccine that uses autologous antigen pre-
senting cells containing a recombinant fusion
protein of prostatic acid phosphatase linked to a
molecule that specifically targets a receptor
expressed on the surface of human prostate
cancer cells [Burch et al., 2004; Schellhammer
and Hershberg, 2005]. Initial results have
demonstrated activity in androgen independent
prostate cancer and have encouraged further
clinical investigations. A randomized phase III
trial studying the effectiveness of APC8015 in
attenuating disease progression and disease-
relatedpain inpatientswhohaveasymptomatic
hormone refractory prostate cancer is currently
is accrual [http://www.cancer.gov/clinicaltrials].
An alternative approach to targeting the
immune system is to target the complement
system. For example, cancer cells overexpress
CD55, a membrane-bound complement regula-
tory protein that is overexpressed in a variety of
cancers and protects cells against complement-
mediated lysis. Currently, an anti-idiotypic
monoclonal antibody, 105AD7, is in clinical
trials as a cancer vaccine that mimics the tumor-
associated antigen CD55 and has demonstrated
the applicability of vaccine-targetedapproaches
in cancer treatment. These strategies could be
used in conjunction with chemotherapy and as
primary therapy early in the disease course.
CONCLUSION/PERSPECTIVE
Table I demonstrates a provocative approach
used to treat a patient with early recurrent
prostate cancer utilizing many of the appro-
aches discussed previously. J.P, a young patient
who failed radical prostatectomy, salvage radia-
tion therapy, and hormonal therapy who now
has biochemical recurrence without additional
evidence of disease. He received three 28 day
cycles of multi-targeted therapy including doc-
etaxel 30 mg/m2 on days 2 and 9, carboplatin on
day 2 to an AUC of 5.0, bevacizumab 5 mg/kg
on day 9, cyclophosphamide 100 mg daily for
20 days of every 30 days, thalidomide 100 mg
daily, calcitriol 0.5 mcg/kg on days 1 and 8,
estramustine 140 mg three times a day and
etoposide 50 mg two times a day on days 1, 2, 3
and 8, 9, 10, prednisone 10 mg daily and GM-
CSF 250mcg three times per week. He received
4mg zolendronic acid onday2.He then received
doxorubicin 10 mg weekly 6 and one dose of
strontium-89 during the second week of doxyr-
ubicin. This multi-modality therapy targeted
early cancer cell growth through combined
chemotherapy and in addition, attempted to
interrupt the vicious cycle created by interac-
tions between the tumor and key components of
the bone microenvironment.
Cancer should be considered a multi-cellular
organ involving both heterogenous cancer cells
TABLE I. One Example of a Hypothetical Treatment Strategy for a Patient With
Early Recurrent Prostate Cancer
Treatment Rationale
Chemotherapyþhormonal therapya Hormonal and chemotherapy will kill cancer cells when they exist in fewer numbers.
Also decreases release of proteases that destroy bone ECM
Bisphosphonate or selective estrogen
receptor modulator treatment
Inhibit bone destruction by osteoclasts. Also inhibits release of tumor growth factors
from the bone matrix
Endothelin 1 inhibitor administrationb Inhibit osteoblast activity. Inhibits osteoblast stimulation of osteoclasts through the
RANK-RNKL axis as well as the release of tumor stimulating cytokines
Limited radiotherapy to lumbar spinec 100% of patients who die with prostate cancer have metastases to their lumbar spine,
suggesting that this is a first stop metastatic spread of prostate cancer and the most
likely place that early disseminated disease is harbored
Treatment with radioisotoped Radioisotopes will target early cancer lesions where destruction of bone is occurring
secondary to the presence of cancer
Administration of a angiogenesis inhibitorb Tumors cannot grow without neovascularization. Most data suggests that
angiogenesis inhibitors work better in earlier disease settings
Administration of tetracycline or green teab Inhibition of proteases
aLimited treatmentwith chemotherapy (six cycles) and 2–3 years of hormonal therapy bases on tumor kinetics and data from adjuvant
radiation studies (9, 49).
bChronic oral treatment.
cTreatment with 30–45 Gy (30).
dTreatment one time.
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aswell asmultiple normal cell types interacting
with the tumor cells. Targeting the tumor cell
itself represents only one avenue for attacking
the disease of advanced prostate cancer. In
order to develop effective therapeutic strategies
it is imperative thatwemovebeyond the concept
of cancer as ‘‘tumor cell’’ and expand the
therapeutic target options to include the cancer
as ‘‘organ.’’ A promising avenue of cancer
therapy resides in the ability to focus on the
recruited and exploited relationships of the
cancer cell with the host environment.
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